Seven new drugs to join $1bn club by 2021, says Clarivate
Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.
The “ Cortellis Drugs to Watch” report, published on Wednesday, March 20, by IP services provider Clarivate Analytics, identified drugs that had the potential to become blockbusters within five years.
A ‘blockbuster’ drug is defined by the common $1 billion annual sales milestone.
According to the report, six out of seven of the drugs will target diseases characterised by genetic disorders or excessive immune response.
The full list includes Upadacitinib by AbbVie, Zolgensma by AveXis, Ultomiris by Alexion, Ar-101 by Aimmune Therapeutics, LentiGlobin by bluebird bio, and Skyrizi by Boehringer Ingelheim and Abbvie.
Roxadustat, another drug on the list, is by AstraZeneca, FibroGen and Astellas.
The genetic disorders treated by the drugs include spinal muscular atrophy, rheumatoid arthritis, and peanut allergy.
Clarivate said this indicates a shift towards medicine targeting niche patient populations, “buoyed by strong collaborations between big and specialty pharma companies to develop these therapies”.
The report also highlighted the positive impact of strategies and incentives put in place by regulatory bodies across the world to encourage drug development for niche markets and unmet medical needs.
Mukhtar Ahmed, president of life sciences at Clarivate, said it was encouraging to see how these incentives along with new discoveries were positively impacting patients in underserved populations.
“This year’s Drugs to Watch report demonstrates the impact of regulators’ incentives, including accelerated reviews and tax breaks, on drug development that targets rare diseases,” he said.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk